The data showed significant improvement in β-cell function and glycemic control, as assessed by fasting, postprandial, and overall (AUC0–24h) glucose and glucagon responses, as well as insulin secretion rate, among those with T2D who received semaglutide. This evidence concerns the gene GCG and type 2 diabetes mellitus.